Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells

Journal of Clinical Investigation

Volumn 100, Issue 9, 1997, Pages 2182-2188

  McCaffrey, Timothy A ^a   Du, Baoheng ^a   Consigli, Seth ^a   Szabo, Paul ^a   Bray, Paula J ^a   Hartner, Lee ^a   Weksler, Babette B ^a   Sanborn, Timothy A ^a   Bergman, Geoffrey ^a   Bush Jr , Harry L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular disease; DNA mutations; Microsatellite instability; Receptors; TGF

Indexed keywords

MICROSATELLITE DNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; GENE DELETION; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SEQUENCE ANALYSIS;

EID: 0030704297     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119754     Document Type: Article

References (43)

1. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond.). 362:801-809.
2. Mehta, V.Y., M.B. Jorgensen, A.E. Raizner, G. Wolde-Tsadik, P.R. Mahrer, and P. Mansukhani. 1995. Spontaneous regression of restenosis: an angiographic study. J. Am. Coll. Cardiol. 26:696-702.
3. Bochaton-Piallat, M.L., F. Gabbiani, M. Redard, A. Desmouliere, and G. Gabbiani. 1995. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am. J. Pathol. 146:1059-1064.
4. Bennett, M.R., G.I. Evan, and S.M. Schwartz. 1995. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 95:2266-2274.
5. Rembold, C. 1996. Could atherosclerosis originate from defective smooth muscle cell death? Perspect. Biol. Med. 39:405-408.
6. McCaffrey, T.A., S. Consigli, B. Du, D.J. Falcone, T.A. Sanborn, A.M. Spokojny, and H. Bush. 1995. Decreased Type II/Type I TGF-β1 receptor ratio in cells derived from human atherosclerotic lesions: conversion from an antiproliferative to profibrotic response to TGF-β1. J. Clin. Invest. 96:2667-2675.
7. Nikol, S., J.M. Isner, J.G. Pickering, M. Kearney, G. Leclerc, and L. Weir. 1992. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J. Clin. Invest. 90:1582-1592.
8. Kojima, S., P.C. Harpel, and D.B. Rifkin. 1991. Lipoprotein (a) inhibits the generation of transforming growth factor-β: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113:1439-1445.
9. Grainger, D.J., P.R. Kemp, J.C. Metcalfe, A.C. Liu, R.M. Lawn, N.R. Williams, A.A. Grace, P.M. Schofield, and A. Chauhan. 1995. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat. Med. 1:74-79.
10. Grainger, D.J., P.L. Weissberg, and J.C. Metcalfe. 1993. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor β. Biochem. J. 294:109-112.
11. Grainger, D.J., P.R. Kemp, A.C. Liu, R.M. Lawn, and J.C. Metcalfe. 1994. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature (Lond.). 370:460-462.
12. McCaffrey, T.A., K.B. Pomerantz, T.A. Sanborn, A.M. Spokojny, B. Du, M.-H. Park, J.E. Folk, A. Lamberg, K.I. Kivirikko, D.F. Falcone, S.B. Mehta, and H.M. Hanauske-Abel. 1995. Specific inhibition of eIF-5A and collagen hydroxylation by a single agent: antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries. J. Clin. Invest. 95: 446-455.
13. Bjorkerud, S. 1991. Effects of transforming growth factor-β1 on human arterial smooth muscle cells in vitro. Arteriosclerosis. 11:892-902.
14. McCaffrey, T.A., and D.J. Falcone. 1993. Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-β in vascular smooth muscle cells. Mol. Biol. Cell. 4:315-322.
15. Wrana, J.L., L. Attisano, R. Wieser, F. Ventura, and J. Massague. 1994. Mechanism of activation of the TGF-β receptor. Nature (Lond.). 370:341-347.
16. Markowitz, S., J. Wang, L. Myeroff, R. Parsons, L.Z. Sun, J. Lutterbaugh, R.S. Fan, E. Zborowska, K.W. Kinzler, B. Vogelstein, et al. 1995. Inactivation of the Type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Wash. DC). 268:1336-1338.
17. Wang, J., L.Z. Sun, L. Myeroff, X.F. Wang, L.E. Gentry, J. Yang, J. Liang, E. Zborowska, S. Markowitz, J.K.V. Willson, and M.G. Brattain. 1995. Demonstration that mutation of the Type II transforming growth factor receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270:22044-22049.
18. Shibata, D., et al. 1996. Genetic diversity in colon carcinoma. Nat. Med. 2:676-681.
19. Benditt, E.P., and J.M. Benditt. 1973. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl. Acad. Sci. U.S.A. 70:1753-1756.
20. Pearson, T.A., J.M. Dillman, K. Soloz, and R.H. Heptinstall. 1978. Clonal markers in the study of the origin and growth of human atherosclerotic lesions. Circ. Res. 11858:28261-11380.
21. Casalone, R., P. Granata, E. Minelli, P. Portentoso, A. Guidici, R. Righi, P. Castelli, A. Socrate, and B. Frigerio. 1991. Cytogenetic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques. Hum. Genet. 87:139-143.
22. Schwartz, S.M., M.W. Majesky, and C.E. Murry. 1995. The intima: development and monoclonal responses to injury. Atherosclerosis. 118:s125-s140.
23. Lin, H.Y., X.F. Wang, E. Ng-Eaton, R.A. Weinberg, and H.F. Lodish. 1992. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell. 68:775-785.
24. Malkhosyan, S., N. Rampino, H. Yamamoto, and M. Perucho. 1996. Frameshift mutator mutations. Nature (Lond.). 382:499-500.
25. Reiss, M., V.F. Vellucci, and Z. Zhou. 1993. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor β1 in murine keratinocytes. Cancer Res. 53:899-904.
26. D'Agostini, F., G. Fronza, P. Campomenosi, A. Izzotti, G.L. Petrilli, A. Abbondandolo, and S. De Flora. 1995. Cancer biomarkers in human atherosclerotic lesions: no evidence of p53 involvement. Cancer Epidemiol. Biomark. Prev. 4:111-115.
27. Chadwick, R.B., M.P. Conrad, M.D. McGinnis, L. Johnston-Dow, S.L. Spurgeon, and M.N. Kronick. 1496. Heterozygote and mutation detection by direct automated fluorescent DNA sequencing using a mutant Taq DNA polymerase. Biotechniques. 20:676-683.
28. Lu, S.-L., W.-C. Zhang, Y. Akiyama, T. Nomizu, and Y. Yuasa. 1996. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 56: 4595-4598.
29. Spandidos, D.A., M. Ergazaki, D. Arvanitis, and H. Kiaris. 1996. Microsatellite instability in human atherosclerotic plaques. Biochem. Biophys. Res. Commun. 220:137-140.
30. Choi, M.E., and B.J. Ballerman. 1995. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-β receptors. J. Biol. Chem. 270:21144-21150.
31. McCaffrey, T.A., D.J. Falcone, C.F. Brayton, L.A. Agarwal, F.P. Welt, and B.B. Weksler. 1989. Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth-β/α2-macroglobulin inactive complex. J. Cell Biol. 109:441-448.
32. McCaffrey, T.A., D.J. Falcone, and B. Du. 1992. Transforming growth factor-β is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-β1. J. Cell. Physiol. 152:430-440.
33. Grainger, D.J., C.M. Witchell, J.V. Watson, J.C. Metcalfe, and P.L. Weissberg. 1993. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor β-like activity from serum. Cardiovasc. Res. 27:2238-2247.
34. Chan, P., M. Patel, L. Betteridge, E. Munro, M. Schachter, J. Wolfe, and P. Sever. 1993. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet (N. Am. Ed.). 341:341-342.
35. Munoz-Antonia, T., X. Li, M. Reiss, R. Jackson, and S. Antonia. 1996. A mutation in the transforming growth factor β Type II receptor gene promoter associated with loss of gene expression. Cancer Res. 56:4831-4835.
36. Kim, I.Y., H.J. Ahn. D.J. Zelner, J.W. Shaw, J.A. Sensibar, J.H. Kim, M. Kato, and C. Lee. 1996. Genetic change in transforming growth factor-β (TGF-β) receptor type 1 gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 56:44-48.
37. King, C.M., E.S. Gillespie, P.G. McKenna, and Y.A. Barnett. 1994. An investigation of mutations as a function of age in humans. Mutat. Res. 316:79-90.
38. Vairapandi, M., and N.J. Duker. 1994. Excision of ultraviolet-induced photoproducts of 5-methylcytosine from DNA. Mutat. Res. 315:85-94.
39. Arvanitakis, L., N. Yaseen, and S. Sharma. 1995. Latent membrane protein-1 induces cyclin D2 expression, pRh hyperphosphorylation, and loss of TGF-β1-mediated growth inhibition in EBV-positive B cells. J. Immunol. 155: 1047-1056.
40. Hayashi, H., S. Abdollah, Y. Qiu, J. Cai, Y.-Y. Xu, B.W. Grinnell, M.A. Richardson, J.N. Topper, M.A. Gimbrone, J.L. Wrana, and D. Falb. 1997. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. Cell. 89:1165-1173.
41. Arteriosclerosis 1981. Report of the Working Group on Arteriosclerosis of the National Heart. Lung, and Blood Institute. NIH Publication. 81-2034.
42. Ishikawa, Y., Y. Fujioka, Y. Kitigawa, A. Nobusawa, A. Takahashi, T. Taniguchi, and M. Yokoyama. 1995. Restenosis after percutaneous transluminal coronary angioplasty in the elderly - risk factor analysis. Nippon Ronen Igakkai Zasshi (Japan). 32:491-496.
43. Denissenko, M.F., A. Pao, M.-S. Tang, and G.P. Pfeifer. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science (Wash. DC). 274:430-432.